EUCTR2015-003036-12-DE进行中（未招募）1 期
A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC) - CARDIAC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- InflaRx GmbH
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients = 18 years old
- •2.Written informed consent
- •3.One of the following cardiac surgical procedures is planned with Cardiopulmonary bypass (CPB):
- •a.Single valve surgery in combination with at least two coronary artery bypass grafts (CABGs)
- •b.Multiple valve surgery with or without CABG
- •c.Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG
- •d.Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG
- •4.Cardiac surgery is performed electively
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Weight > 130 kg
- •2.The following cardiac surgical procedures:
- •a.Cardiac surgical procedure is planned as minimally invasive procedure (e.g., without thoracotomy or with lateral incision, minimal thoracotomy)
- •b.Cardiac surgery with an expected CPB time less than 100 minutes
- •3.Other cardiac and vascular diseases and/or procedures:
- •a.Prior cardiac surgery within the past 6 months
- •b.History of heart transplantation or planned heart transplantation
- •c.Requiring inotropic, vasopressor or mechanical circulatory support
- •d.Requiring ventilatory support
- •4.Other disease or condition that is likely to interfere with the evaluation of the study drug:
- •a.Active infective endocarditis
- •b.Stroke or transient ischemic attack (TIA) within the last 6 months
- •c.Concomitant disease with a life expectancy of less than 6 months
- •d.Cardiopulmonary resuscitation within the last 4 weeks
- •e.Patients requiring renal replacement therapy
- •5.Cerebrovascular disease requiring concomitant carotid endarterectomy
- •6.Active infection with or without a temperature greater than 38°C
- •7.Presence of systemic inflammatory response syndrome defined as occurrence of at least 2 out of the following 4 criteria:
- •a.Fever > 38.0°C or hypothermia < 36.0°C
- •b.Tachycardia > 90 beats/minute
- •c.Tachypnea > 20 breaths/minute
- •d.Leucocytosis > 12 x 109/l or leucopenia < 4 x 109/l or > 10% immature neutrophils (bands)
- •8. Positive test for human immunodeficiency virus (HIV), hepatitis B or C
- •9.One of the following abnormal laboratory results:
- •a.Hemoglobin < 5 mmol/l (< 8.06 g/dl)
- •b.Total bilirubin = 2 x upper normal limit (UNL)
- •c.CRP > 3 x UNL
- •d.ALAT > 3 x UNL
- •e.ASAT > 3 x UNL
- •f.White blood cell count < 2,500/mm³
- •g.White blood cell count > 12,000/mm³
- •10.Prohibited concomitant medications:
- •a.Immunomodulatory drugs within past 30 days (e.g., TNF-inhibitors)
- •b.Immunosuppressive drugs within past 30 days (e.g., cyclosporine, tacrolimus)
- •c.High dose corticosteroids (e.g., > 50 mg prednisone/day or equivalent) within past 14 days
- •d.Any systemic anticancer treatment within the past 3 months
- •11.Planned corticosteroid pulse therapy to prevent SIRS
- •12. Patients with known hypersensitivity to any constituent of the
- •investigational medicinal product (IMP)
- •13.General exclusion criteria:
- •a.Pregnant (in women of childbearing potential an urine pregnancy test has to be performed) or breast-feeding women
- •b.Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial
- •c.Participation in any interventional clinical trial within the last three months
- •d.Prior randomization in this clinical trial (screen failures can be re-screened, if appropriate)
- •e.Alcohol, drug, or medication abuse
- •f.Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor
- •g.No commitment to full aggressive life support (e.g., DNR order)
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes.EUCTR2022-000743-68-ITDOMPé FARMACEUTICI S.P.A.86
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29EUCTR2013-001037-40-DEInflaRx GmbH72
进行中（未招募）
不适用
A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI) - N/ARecurrence of Clostridium difficile Infection (CDI)MedDRA version: 12.0Level: LLTClassification code 10006834Term: C.difficile diarrheaMedDRA version: 12.0Level: LLTClassification code 10006835Term: C.difficile diarrhoeaMedDRA version: 12.0Level: LLTClassification code 10012734Term: Diarrhea, Clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10054236Term: Clostridium difficile infectionEUCTR2008-004907-69-GBSanofi Pasteur Inc.612
进行中（未招募）
1 期
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failurePatient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2015-005607-92-PLQUANTUM GENOMICS75
进行中（未招募）
1 期
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 19.1Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2015-005607-92-HUQuantum Genomics75